MTOR and cancer: However, translational attempts of mTOR inhibition have been unsuccessful in ameliorating cognitive functioning, behavioral problems, autism and neuropsychological deficits in children ages 4-17 treated with Everolimus—another mTOR inhibitor that was previously FDA approved for cancer treatments [120].